**LETTER**

**Metabolic gatekeeper function of B–lymphoid transcription factors**

Lai N. Chan¹,², Zhengshan Chen¹,², Daniel Braas¹, Jae–Woong Lee¹,², Gang Xiao¹,², Huimin Geng³, Kadiyre Nehir Cosgun¹,², Christian Hurtz⁴, Seyedmehideh Shojaee⁵, Valeria Cazzaniga⁶, Hilde Schjerven⁷, Thomas Ernst⁸, Andreas Hochhaus⁹, Steven M. Kornblau¹⁰, Marina Konopleva¹, Miles A. Pufall¹, Giovanni Cazzaniga⁸, Grace J. Liu¹, Thomas A. Milne¹⁰, H. Phillip Koeffler¹¹,¹², Theodora S. Ross¹³, Isidro Sánchez–García¹⁴, Arndt Borkhardt¹⁵, Keith R. Yamamoto⁴, Ross A. Dickins⁹, Thomas G. Graeber³ & Markus Müschen¹,²

B-lymphoid transcription factors, such as PAX5 and IKZF1, are critical for early B-cell development¹,², yet lesions of the genes encoding these transcription factors occur in over 80% of cases of pre-B-cell acute lymphoblastic leukaemia (ALL)³,⁴. The importance of these lesions in ALL has, until now, remained unclear. Here, by combining studies using chromatin immunoprecipitation with sequencing and RNA sequencing, we identify a novel B-lymphoid program for transcriptional repression of glucose and energy supply. Our metabolic analyses revealed that PAX5 and IKZF1 enforce a state of chronic energy deprivation, resulting in constitutive activation of the energy-stress sensor AMPK³–⁷. Dominant-negative mutants of PAX5 and IKZF1, however, relieved this glucose and energy restriction. In a transgenic pre-B ALL mouse model, the heterozygous deletion of Pax5 increased glucose uptake and ATP levels by more than 25-fold. Reconstitution of PAX5 and IKZF1 in patients with pre-B ALL restored a non-permissive state and induced energy crisis and cell death. A CRISPR/Cas9-based screen of PAX5 and IKZF1 transcriptional targets identified the products of NR3C1 (encoding the glucocorticoid receptor)⁵, TXNIP (encoding a glucose-feedback sensor)⁹ and CNR2 (encoding a cannabionoid receptor)¹⁰ as central effectors of B-lymphoid restriction of glucose and energy supply. Notably, transport-independent lipophilic methyl-conjugates of pyruvate and tricarboxylic acid cycle metabolites bypassed the gatekeeper function of PAX5 and IKZF1 and readily enabled leukemic transformation. Conversely, pharmacological TXNIP and CNR2 agonists and a small-molecule AMPK inhibitor strongly synergized with glucocorticoids, identifying TXNIP, CNR2 and AMPK as potential therapeutic targets. Furthermore, our results provide a mechanistic explanation for the empirical finding that glucocorticoids are effective in the treatment of B-lymphoid but not myeloid malignancies. Thus, B-lymphoid transcription factors function as metabolic gatekeepers by limiting the amount of cellular ATP to levels that are insufficient for malignant transformation.

The transcription factors PAX5, IKZF1, EBF1 and TCF3 are critical for normal B-cell development¹¹ and are opposed by CEBPA, a central driver of myeloid differentiation¹². In adipocytes, EBF1 decreases glucose transport¹³, whereas CEBPA promotes glucose transport¹⁴. Transforming oncogenes (for example, BCR–ABL1 or RAS) impose substantial metabolic requirements on the supply of glucose and energy. Given the high frequency of genetic lesions present on B-lymphoid transcription factors in pre-B ALL, we investigated whether these transcription factors restrict the supply of glucose and energy, and thus represent a metabolic barrier against malignant transformation. Studying inactivating lesions in PAX5, IKZF1, EBF1 and TCF3 in 279 patient samples from clinical trials for children and adults (see Methods), we found mutations or deletions in 209 cases. The patient-derived pre-B ALL xenografts that we studied here exhibited abnormal expression of PAX5 and IKZF1 proteins (Extended Data Fig. 1b, c). Analysis of chromatin immunoprecipitation with sequencing (ChIP–seq) data of human B-cells revealed that PAX5, IKZF1, EBF1 and TCF3 bind to promoter regions of INSR, GLUT1, GLUT6, G6PD and HK2, genes encoding proteins that enable glucose uptake and utilization. We also observed binding peaks at promoter regions of genes that encode negative regulators of glucose uptake, including NR3C1, TXNIP and CNR2. Recruitment of PAX5 to these promoters was confirmed by single-locus quantitative ChIP (Extended Data Fig. 1d, e). Inducible reconstitution of mouse Pax5 (Gene Expression Omnibus (GEO) accession number: GSE52870) in Pax5-deficient pre-B leukaemia cells downregulated multiple mediators of glucose uptake, whereas the mRNA levels of glucose-transport inhibitors increased (Mxip, Txnip, Cnr2; Extended Data Fig. 1a).

We verified these results in four patient-derived pre-B ALL samples. Inducible reconstitution of wild-type transcription factors in patient-derived pre-B ALL cells lacking functional PAX5 or IKZF1 (Fig. 1a) induced activation of the LKB1–AMPK energy-stress-sensor pathway¹⁵. As would be consistent with the depletion of glucose and energy, reconstitution of IKZF1 and PAX5 diminished AKT activation. Similarly, reconstitution of both IKZF1 and PAX5 decreased protein levels of the insulin receptor, the glucose transporters GLUT1, GLUT3 and GLUT6, and the effectors of glucose metabolism HK2, HK3, PFKL, PGAM, PYGL and G6PD. By contrast, PAX5 and IKZF1 induced strong expression of the glucose-transport inhibitors NR3C1, TXNIP and CNR2¹⁶–¹⁰. For loss-of-function studies, dominant-negative variants of IKZF1 (DN–IKZF1, lacking zinc fingers 1–4) and PAX5 (DN–PAX5; a PAX5–ETV6 fusion gene) were cloned from patient samples and expression was induced in two pre-B ALL xenografts carrying wild-type IKZF1 and PAX5 alleles (Extended Data Fig. 2a).

1Department of Systems Biology, Beckman Research Institute and City of Hope National Medical Center, Pasadena, California 91016, USA. ²City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA. ³Department of Molecular and Medical Pharmacology, UCLA Metabolomics Center and Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California 90095, USA. ⁴Departments of Laboratory Medicine and Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California 94143, USA. ⁵HämatoLOGIKOnologie, Klinik für Innere Medizin II, Universitätshämann Jena, 07743 Jena, Germany. ⁶Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. ⁷Department of Biochemistry, University of Iowa, Iowa City, Iowa 52242, USA. ⁸Centro Ricerca Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale S. Gerardo, Medical Center, Dallas, Texas 75390, USA. ⁹Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. ¹⁰Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. ¹¹Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90095, USA. ¹²Department of Internal Medicine and Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. ¹³Department of Internal Medicine and Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. ¹⁴Department of Internal Medicine and Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. ¹⁵Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
most PAX5- and IKZF1-induced changes in protein expression were reversed by DN-IKZF1 and DN-PAX5 (Fig. 1a).

Inducible reconstitution of PAX5 or IKZF1 in human pre-B ALL cells resulted in the depletion of cells in competitive-growth assays, in parallel with reduced glucose uptake and ATP depletion. Conversely, DN-PAX5 and DN-IKZF1 conferred a net survival advantage, as measured in competitive-growth assays, and increased glucose uptake and cellular ATP levels (Fig. 1b, c). Since oncogenic kinases such as DN-PAX5 and DN-IKZF1 conferred a net survival advantage, as measured by flow cytometry, P values were calculated by two-way ANOVA (left, line graphs); glucose uptake and ATP levels analysed by two-tailed t-test (right, bar graphs). Data are mean ± s.d. (n = 3 independent experiments). For gel source data, see Supplementary Fig. 1.

Both B-lymphoid and myeloid leukaemia typically arise from a multipotent progenitor cell and often carry the same oncogenes. Despite this common origin, B-lymphoid and myeloid leukaemia differ fundamentally in their biological and clinical characteristics. Given that myeloid or B-lymphoid fates are instructed by transcription factors (myeloid by CEBPA, lymphoid by IKZF1 and PAX5) that regulate glucose and energy metabolism14,15, we investigated whether myeloid and B-cell identities are linked to distinct metabolic states. Metabolic comparisons of B-lineage Philadelphia-chromosome-positive (Ph+) ALL and myeloid chronic myeloid leukaemia (CML) cells revealed marked differences. Intracellular glucose and pyruvate were present at notably

**Figure 1** | A B-lymphoid transcriptional program to regulate factors of glucose uptake and utilization. a, Western blots showing differences in levels of the indicated proteins in patient-derived IKZF1<sup>WT</sup>, IKZF1<sup>Δ</sup>, PAX5<sup>WT</sup> and PAX5<sup>Δ</sup> pre-B ALL cells transduced with PAX5, IKZF1<sup>WT</sup>, DN-PAX5, DN-IKZF1 or an empty vector (EV). b, c, Patient-derived pre-B ALL cells with wild-type or deleted PAX5 (PAX5<sup>WT</sup> and PAX5<sup>Δ</sup>, respectively); b) and wild-type or deleted IKZF1 (IKZF1<sup>WT</sup> and IKZF1<sup>Δ</sup>, respectively); c) were transduced with GFP-tagged PAX5 (b), IKZF1 (c), DN-PAX5 (b) or DN-IKZF1 (c); empty vector acts as a control. Enrichment or depletion of GFP<sup>+</sup> cells was monitored by flow cytometry. P values were calculated by two-way ANOVA (left, line graphs); glucose uptake and ATP levels analysed by two-tailed t-test (right, bar graphs). Data are mean ± s.d. (n = 3 independent experiments). For gel source data, see Supplementary Fig. 1.

**Figure 2** | LKB1–AMPK is required to balance glucose and energy metabolism in pre-B ALL. a, b, Heat map of metabolomics (n = 2 per group, each in triplicate; a) and western blots (n = 4; b) of patient-derived BCR–ABL1<sup>+</sup> leukaemia samples. c, Glucose uptake and ATP levels during B-to-myeloid cell reprogramming in Lkb1<sup>−/−</sup>-pre-B ALL cells in the absence of Lkb1 deletion (n = 4). d, Fold change of pre-B ALL cells carrying GFP-tagged Cre following Cre-mediated Lkb1 deletion upon reprogramming of patient-derived pre-B ALL cells following deletion of Lkb1 or Ampkα2 (n = 3 independent experiments). e, Kaplan–Meier analysis ( Mantel–Cox log-rank test) of recipient mice (n = 7 per group) injected with pre-B ALL cells following 24 h treatment with 4-OHT to induce deletion of Lkb1 or Ampkα2. g, Patient-derived pre-B ALL cells treated with BML275, prednisolone or a combination of the two (n = 3) as indicated, assessed by combination index (CI). Data are mean ± s.d. and assessed by two-tailed t-test (c) or two-way ANOVA (d, e). For gel source data, see Supplementary Fig. 1.
higher levels (approximately 10–13-fold and 6–11-fold, respectively) in patient-derived myeloid cells compared to B-lymphoid leukaemia cells. Myeloid leukaemia cells had abundant ATP reserves, whereas ATP levels in B-lineage leukaemia cells were low, indicating a state of chronic energy stress (Fig. 2a). Bioenergetic analyses revealed lower glycolytic reserves (approximately 5–14-fold) in B-lymphoid than in myeloid leukaemia cells. Basal and maximum respiration and mitochondrial ATP levels were substantially lower in B-lineage leukaemia cells (Extended Data Fig. 3a), resulting in the constitutive activation of the LKB1–AMPK energy-sensor pathway. Ph+ ALL cells expressed effectors of glucose utilization (GLUT1, HK2, HK3, G6PD) at more than 10-fold lower levels than myeloid leukaemia cells, whereas the expression of glucose transport inhibitors (NR3C1, TXNIP, CNR2; Fig. 2b) was substantially higher in B-lymphoid cells than in CML cells. To examine the effects of B-cell- and myeloid-lineage identity in genetically identical mouse leukaemia cells, we studied the reprogramming of B-cells through the inducible overexpression of the myeloid transcription factor CEBPα. Studying changes in gene expression during B-to-myeloid cell reprogramming23, we observed the upregulation of Insr, Glut1, Glut6, Hk2, Hk3, G6PD and Pygl, effector molecules of glucose transport and utilization. B-to-myeloid cell reprogramming markedly increased glucose uptake and cellular ATP levels (Fig. 2c), resulting in decreased Lkb1–AMPK pathway activity (Extended Data Fig. 3). Mirroring these differences, the Cre-mediated deletion of Shk11 (also known as Lkb1) induced cell death in B-lineage ALL cells, but accelerated proliferation in B-to-myeloid reprogrammed cells (Fig. 2d).

For this reason, we studied the consequences of inducible ablation of Lkb1 and Prkaa2 (also known as Ampka2), expression levels of which were upregulated at the pre-B-cell stage compared to later stages of B-cell development (GEO accession number: GSE38463). The Cre-mediated 4-hydroxytamoxifen (4-OHT)-induced deletion of Lkb1 or Ampka2 led to rapid leukaemia cell death, prevented malignant transformation of pre-B cells and affected the development of leukaemia in vivo. Deletion of Lkb1 or Ampka2 significantly prolonged the overall survival of mouse recipients (Fig. 2e, f and Extended Data Fig. 4).

The genotyping of leukaemias revealed that floxed alleles of Lkb1 and Ampka2 were retained in all cases (Extended Data Fig. 4i), indicating strong positive selection for the few clones that escaped Cre-mediated deletion.

A recent study showed that deletion of Prkaa1 (also known as Ampkα1) induced acceleration of mature B-cell lymphoma17, which is seemingly at odds with our findings in pre-B ALL. Moreover, genetic lesions in PAX5, IKZF1, EBF1 and TCF3 are common in pre-B ALL but very rare in mature B-cell lymphomas (Extended Data Fig. 5). We therefore investigated whether LKB1–AMPK pathway function defines a stage-specific metabolic checkpoint during early B-cell development, when B-lymphoid transcription factors are most active. To this end, we crossed Lkb1fl/fl mice with Cre deleter strains for deletion of Lkb1 at early (Mb1) and late (Cd21) stages of B-cell development. Although loss of Lkb1 at the pre-B-cell stage resulted in a complete block of B-cell development, deletion of Lkb1 in mature Cd21+ B-cells had no substantial effect on survival and proliferation (Extended Data Fig. 4a). These findings explain the apparent differences between pre-B ALL and mature B-cell lymphoma17, and also reveal a metabolic checkpoint function for Lkb1 at the pre-B-cell stage.

In both myeloid and B-lineage leukaemia cells, acute deletion of Lkb1 resulted in the loss of Ampk activity and inhibited phosphorylation of Ampk substrates (Extended Data Figs 6, 7). Although biochemical changes in response to Lkb1 deletion were similar, the functional outcomes were markedly different in myeloid and B-lymphoid cells. Lkb1 deletion in myeloid leukaemia cells stimulated Akt signalling, induced proliferation and increased ATP levels, glucose uptake, glycolytic capacity and glycolytic reserve, whereas cell-cycle checkpoint molecules were downregulated. By contrast, deletion of Lkb1 or Ampka2 in B-lymphoid leukaemia cells decreased cell viability and cell numbers, and activated cell-cycle checkpoint proteins while decreasing glucose uptake, mitochondrial respiration and ATP levels (Extended Data Figs 6, 7). Similarly, the inducible deletion of Lkb1 in B-lymphoid ALL cells caused cell death and loss of colony-forming capacity and delayed the onset of leukaemia, as well as prolonging the
survival of transplant-recipient mice in vivo (Extended Data Fig. 4). High expression levels of LKB1 and AMPK are associated with poor clinical outcome in patients with B-lymphoid but not myeloid leukaemia (Extended Data Fig. 5).

Unlike mature B-cells or myeloid cells, patient-derived pre-B ALL cells were highly sensitive to BML275, a small-molecule inhibitor of AMPK\(^{18}\). BML275 abolished AMPK enzymatic activity and AKT signalling, and induced cell death resulting from energy stress and AMP accumulation. BML275 treatment of patient-derived pre-B ALL cells obliterated glycolytic flux and mitochondrial respiration, but had no considerable effects on myeloid leukaemia or mature B-cell lymphoma cells (Extended Data Fig. 8). Given that both AMPK inhibition and glucocorticoid treatment reduced glucose uptake in pre-B ALL, we tested the pharmacological interactions of an AMPK inhibitor and glucocorticoids. BML275 and prednisolone demonstrated strong synergistic activity in patient-derived pre-B ALL cells, suggesting that inhibition of AMPK represents a previously unrecognized vulnerability in pre-B ALL that can be exploited in combination therapies with glucocorticoids (Fig. 2g, Extended Data Fig. 10a and Supplementary Table 1).

To measure the mechanistic contribution of PAX5 target genes to PAX5-mediated tumour suppression, we performed a CRISPR-based genetic screen. For this screen, we utilized two approaches. First, we used transcriptional activation (CRISPR-a)\(^{19}\) to counteract repression by PAX5, which resulted in a survival advantage when some PAX5-target genes were activated, although the effects were relatively small.

Second, we performed CRISPR/Cas9-mediated deletion of the PAX5 target genes were activated, although the effects were relatively small. PAX5 and IKZF1, which resulted in a survival advantage when some PAX5- and IKZF1-exerted their tumour-suppressor function, at least in part, through the transcriptional repression of glucose transport and increased ATP levels (Fig. 3a). Although inducible PAX5 expression caused cell death in mouse pre-B ALL cells, the tumour-suppressive effect of PAX5 was mitigated upon genetic loss of Nr3c1, Txnip and Cnr2 (Fig. 3b). CRISPR/Cas9-mediated deletion of Nr3c1, Txnip and Cnr2 in patient-derived pre-B ALL cells further corroborated the role of these negative regulators of glucose transport in human disease and PAX5-mediated tumour suppression (Fig. 3c).

For the past five decades, glucocorticoids have been a central component of the therapy regimen for patients with pre-B ALL. Glucocorticoids are highly active in B-lymphoid ALL, but ineffective in the treatment of myeloid leukaemia\(^{20}\); however, the underlying reason for this difference had remained elusive. Studying patient-derived leukaemia samples, we found 6–20-fold higher levels of Nr3c1 protein in B-lymphoid compared to myeloid leukaemia cells (Fig. 2b). Whereas IKZF1 and PAX5 positively regulated Nr3c1 levels, DN-IKZF1, DN-PAX5 and B-to-myeloid cell reprogramming erased Nr3c1 expression (Fig. 1 and Extended Data Fig. 3). We therefore tested whether B-lymphoid transcription factors set the threshold for glucocorticoid responses. Reconstitution of PAX5 and IKZF1 in pre-B ALL patient samples significantly shifted dose–response curves. Similarly, any response to dexamethasone was largely abolished upon induction of DN-IKZF1 and DN-PAX5 (Extended Data Fig. 9e). Loss of Cnr2 and Txnip rescued prednisolone-induced cell death in pre-B ALL cells (Extended Data Fig. 9c), suggesting that glucocorticoid responses are influenced by factors that affect glucose uptake. On this basis, we tested the drug interactions between glucocorticoids and the Cnr2 agonist HU308 or the TXNIP agonists 3-O-methylglucose (3-OMG) and d-allose\(^{21,22}\). In patient-derived pre-B ALL cells, HU308, 3-OMG or d-allose worked in synergy with glucocorticoid treatment (Extended Data Fig. 10 and Supplementary Table 1), suggesting that Cnr2 and TXNIP cooperate with Nr3c1 to exacerbate B-cell-intrinsic ATP depletion.

Our results indicate that B-lymphoid transcription factors, including PAX5 and IKZF1, exert their tumour-suppressor function, at least in part, through the transcriptional repression of glucose transport and the restriction of metabolites that can fuel the tricarboxylic acid cycle. The restriction of the supply of glucose and energy that is imposed by B-lymphoid transcription factors is necessary to prevent the malignant transformation of pre-B cells. On the basis of this scenario, we predict that transport-independent glucose metabolites can bypass...
the gatekeeper function of PAX5 and IKZF1. Reconstitution of PAX5 and IKZF1 was induced in haploinsufficient patient-derived pre-B ALL cells cultured in the presence of vehicle, transport-independent lipophilic methyl pyruvate or the tricarboxylic-acid-cycle intermediates dimethyl succinate (DMS) and oxaloacetate (OAA; Fig. 4a). Reconstitution of PAX5 and IKZF1 induced a survival disadvantage in competitive-growth assays in the presence of vehicle controls. However, dual (DMS and OAA) and triple (DMS, OAA and methyl pyruvate) combinations almost entirely prevented PAX5- and IKZF1-induced leukaemia cell death (Fig. 4a).

Conditional expression of GFP-tagged BCR–ABL1 from a recently developed conditional knock-in allele23 was insufficient to drive the malignant transformation of pre-B cells. BCR–ABL1 \( \text{p}210 \) pre-B cells from these mice remained in a pre-leukaemic state and did not give rise to overt disease. When cultured under control conditions, BCR–ABL1 \( \text{p}210 \) pre-B cells formed few colonies and exhibited low BCR–ABL1 kinase activity (Fig. 4b, c). However, when BCR–ABL1 \( \text{p}210 \) pre-B cells were incubated for 4 weeks with DMS and OAA, colony numbers increased (vehicle-treated, \( \pm 0.5 \); DMS/OAA-treated, 502 \( \pm 79 \)), as did BCR–ABL1 expression and activity (Fig. 4b, c). Notably, vehicle-treated BCR–ABL1 \( \text{p}210 \) pre-B cells failed to initiate leukaemia when injected into sub-lethally irradiated NSG (Non-obese diabetic/severe combined immune-deficient) mouse recipients. However, six of the seven NSG recipients developed fatal disease within 5 weeks of injection when BCR–ABL1 \( \text{p}210 \) pre-B cells were cultured in the continuous presence of DMS and OAA (Fig. 4d, e). In the absence of DMS and OAA, only 0.014% of BCR–ABL1 \( \text{p}210 \) pre-B cells expressed the BCR–ABL1–GFP fusion protein at detectable levels. Even when treated with DMS and OAA, the fraction of cells expressing BCR–ABL1–GFP did not exceed 1% (Fig. 4b), suggesting that metabolite-induced transformation is a rare event.

During early B-cell development, pre-B cells are under intense selective pressure. Collateral damage during V(D)J-recombination represents a main driver of malignant transformation24,25. We propose that B-lymphoid transcription factors function as metabolic gatekeepers, limiting the supply of glucose and energy to levels that are below the minimum requirements for malignant transformation (Fig. 4f). Pre-leukaemic B-cell clones carrying oncogenic lesions are frequently found in neonatal cord blood26,27. In addition, small fractions of normal B cells in healthy adults carry silent oncogenes28,29. These findings indicate that pre-leukaemic B-cell clones frequently occur in healthy individuals, both during childhood and later in life. We conclude that B-lymphoid repression of glucose uptake and energy supply represents a previously unrecognized metabolic barrier against malignant pre-B-cell transformation and that TXNIP, CNR2 and AMPK are novel targets for the treatment of pre-B ALL.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 3 October; accepted 21 December 2016.
Published online 13 February 2017.
METHODS

Primary human samples and cell lines. Pre-B acute lymphoblastic leukaemia (ALL) cells were obtained from patients who gave informed consent in compliance with the guidelines of the Internal Review Board of the University of California San Francisco (Supplementary Table 2). Leukaemia cells from bone marrow biopsy of patients with ALL were xenografted into subcutaneously irradiated NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice via tail vein injection. After passaging, leukaemia cells were collected. Cells were cultured on OP9 stroma cells in minimum essential medium α (MEM; Invitrogen), supplemented with 20% fetal bovine serum (FBS), 2 mM l-glutamine, 1 mM sodium pyruvate, 100 IU/ml penicillin and 100 μg/ml streptomycin. Primary chronic myeloid leukaemia (CML) cases were obtained with informed consent from the University Hospital Jena in compliance with institutional internal review boards (including the IRB of the University of California San Francisco; Supplementary Table 3). Cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen) supplemented with 20% BIF serum substitute (StemCell Technologies), 100 IU/ml penicillin and 100 μg/ml streptomycin; 25 μM 3-mercaptopethanol; 100 μg/ml SCF; 100 ng/ml IL-3, and 20 ng/ml IL-6. Human cell lines (Supplementary Table 2) were obtained from DSMZ and were cultured in Roswell Park Memorial Institute medium (RPMI-1640; Invitrogen) supplemented with GlutaMAX containing 20% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin. Cell cultures were kept at 37°C in a humidified incubator in a 5% CO₂ atmosphere. None of the cell lines used was found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. All cell lines were authenticated by STR profiles and tested negative for mycoplasma.

Small-molecule inhibitors and activators and metabolites. BML275 (water-soluble) and imatinib were obtained from Santa Cruz Biotechnology and LC Laboratories, respectively. Stock solutions were prepared in DMSO or sterile water at 10 mM and stored at −20°C. Prednisolone and dexamethasone (water-soluble) were purchased from Sigma-Aldrich and were resuspended in ethanol or sterile water, respectively, at 10 mM. Stock solutions were stored at −20°C. Fresh solutions (pH-adjusted) of methyl pyruvate, OAA, 3-OMG (an agonist of TXNIP), d-allose (an agonist of TXNIP) and recombinant insulin (Sigma-Aldrich) were prepared for each experiment. DMS was obtained from Acros Organics, and fresh solutions (pH-adjusted) were prepared before each experiment. For competitive-growth assays, 5 mM/l methyl pyruvate, 5 mM/l dimethyl succinate (DMS) and 5 mM/l OA were used. The CNR2 agonist HU308 was obtained from Cayman Chemical.

Mouse leukaemia models. To avoid inflammation-related effects in mice, bone marrow cells were extracted from mice (Supplementary Table 4) younger than 6 weeks of age without signs of inflammation. All mouse experiments were conducted in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee. Bone marrow cells were obtained by flushing cavities of femur and tibia with PBS. After filtration through a 70-μm filter and depletion of erythrocytes using a lysis buffer (BD PharmLyse, BD Biosciences), washed cells were either frozen for storage or subjected to further experiments. Bone marrow cells were cultured in IMDM (Invitrogen) with GlutaMAX containing 20% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 50 μM 3-mercaptopethanol. To generate pre-B ALL (Ph+ ALL-like) cells, bone marrow cells were cultured in 10 ng/ml recombinant mouse IL-7 (PeproTech) and retrovirally transformed by BCR–ABL1. BCR–ABL1-transformed pre-B ALL cells were propagated only for short periods of time and usually not for longer than 2 months to avoid acquisition of additional genetic lesions during long-term cell culture. To generate myeloid leukaemia (CML-like) cells, the myeloid-restricted protocol described previously was used. Bone marrow cells were cultured in 10 ng/ml recombinant mouse IL-3, 25 ng/ml recombinant mouse IL-6, and 50 ng/ml recombinant mouse Lkb1 (PeproTech) and retrovirally transformed by BCR–ABL1. Immunophenotypic characterization was performed by flow cytometry. For conditional deletion, a 4-OHT-inducible, Cre-mediated deletion system was used. For retroviral constructs used, see Supplementary Table 5.

Retroviral and lentiviral constructs and transduction. Transfection of retroviral constructs (Supplementary Table 5) was performed using Lipofectamine 2000 (Invitrogen) with Opti-MEM medium (Invitrogen). Retroviral supernatant was produced by co-transfecting HEK 293FT cells with the plasmids pHT60 (gag-pol) and pHIT123 (ecotropic env). Lentiviral supernatant was produced by co-transfecting HEK 293FT cells with the plasmids pCDNL-BH and VSV-G or EM140. 293FT cells were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) with GlutaMAX containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 25 mM/l HEPES, 1 mM/l sodium pyruvate and 0.1 mM/l non-essential amino acids. Regular medium was replaced after 16 h by growth medium containing 10 mM/l sodium butyrate. After incubation for 8 h, the medium was changed back to regular growth medium. After 24 h, retroviral supernatant was collected, filtered through a 0.45-μm filter and loaded by centrifugation (2,000g, 90 min at 32°C) onto 50 μg/ml RetroNectin-(Takara) coated non-tissue-6-well plates. Lentiviral supernatant produced with VSV-G was concentrated using Lenti-X Concentrator (Clontech), loaded onto RetroNectin-coated plates and incubated for 15 min at room temperature. Lentiviral supernatant produced with EM140 was collected, loaded onto RetroNectin-coated plates and incubated for 30 min at room temperature. Per well, 2–3 × 10⁶ cells were transduced by centrifugation at 600g for 30 min and maintained for 48 h at 37°C with 5% CO₂ before transferring into culture flasks. For cells transduced with lentiviral supernatant produced with EM140, supernatant was removed the day after transduction and replaced with fresh culture medium. Cells transduced with oestrogen-receptor fusion proteins were induced with 4-OHT (1 μmol/l). Cells transduced with constructs carrying an antibiotic-resistance marker were selected with its respective antibiotic.

Inducible gain- and loss-of-function of IKZF1 and PAX5. For loss-of-function studies, dominant-negative variants of IKZF1 (DN-IKZF1, lacking the IKZF1 zinc fingers 1–4) and PAX5 (DN-PAX5; PAX5–ETV6 fusion) were cloned from patient samples. Expression of DN-IKZF1 was induced by doxycycline (1 μg/ml), while activation of DN-PAX5 was induced by 4-OHT (1 μg/ml) in patient-derived pre-B ALL cells carrying IKZF1 and PAX5 wild-type alleles, respectively. Inducible reconstitution of wild-type IKZF1 and PAX5 in haploinsufficient pre-B ALL cells carrying deletions of either IKZF1 (IKZF1Δ1) or PAX5 (PAX5Δ3) were also studied. Lentiviral constructs used are listed in Supplementary Table 5. A doxycycline-inducible Tet³⁴ vector system was used for inducible expression of PAX5 in mouse BCR–ABL1 pre-B ALL. The retroviral constructs used are listed in Supplementary Table 5. CEBPα-mediated reprogramming of pre-B cells into the myeloid lineage. To study the effects of B-cell versus myeloid lineage identity in genetically identical mouse leukaemia cells, a doxycycline-inducible Tet³⁴ CEBPα vector system was used to reprogram B cells. Mouse BCR–ABL1 pre-B ALL cells expressing doxycycline-inducible CEBPα or an empty vector were induced with doxycycline (1 μg/ml). Conversion from the B-cell lineage (CD19+Mac1−) to the myeloid lineage (CD19−Mac1+) was monitored by flow cytometry. For western blots, B-lineage cells (CD19+Mac1−) and CEBPα-reprogrammed cells (CD19+Mac1+) were sorted from cells expressing an empty vector or CEBPα, respectively, following doxycycline induction. For metabolic assays, sorted B-lineage cells and CEBPα-reprogrammed cells were cultured (with doxycycline) for 2 days following sorting, and were then seeded in fresh medium for measurement of glucose consumption (normalized to cell numbers) and total ATP levels (normalized to total protein).

To study Lkb1 deletion in the context of CEBPα-mediated reprogramming, BCR–ABL1-transformed Lkb1−/− pre-B ALL cells expressing doxycycline-inducible CEBPα were transduced with 4-OHT(1 μg/ml) inducible Cre-GFP (Cre-ER²-GFP). Without sorting for GFP+ cells, cells were induced with doxycycline and 4-OHT. Viability (expressed as relative change of GFP− cells) was measured separately in B-lineage (gated on CD19+Mac1−) and myeloid lineage (gated on CD19−Mac1+) populations.

To study whether Lkb1 deletion causes CEBPα-dependent effects on metabolism and signalling, Lkb1−/− BCR–ABL1 B-lineage ALL cells expressing doxycycline-inducible CEBPα or an empty vector were transduced with 4-OHT-inducible Cre-GFP. After sorting for GFP+ populations, cells were induced with doxycycline. B-lineage cells (CD19+Mac1−) and CEBPα-reprogrammed cells (CD19+Mac1+) were sorted from cells expressing an empty vector or CEBPα, respectively. Sorted B-lineage cells with doxycycline and induced with 4-OHT. Protein lysates were collected on day 2 following 4-OHT induction. For metabolomics, sorted cells were re-seeded in fresh medium on day 2 following 4-OHT induction and collected for metabolite analysis.

CRISPR-mediated gene editing. For CRISPR/Cas9-mediated deletion of target genes, all constructs including lentiviral vectors expressing gRNA and Cas9 nucleases were purchased from Transcom Technologies (Supplementary Table 5; see Supplementary Table 6 for gRNA sequences). In brief, patient-derived pre-B ALL cells transduced with GFP-tagged, 4-OHT-inducible PAX5 or an empty vector were transduced with pCLIP-hCMV-Cas9-Nuclease Blasticidin-resistant cells were subsequently transduced with pCLIP-hCMV-gRNA-RFP. Non-targeting gRNA was used as control.

Constructions including lentiviral vectors expressing gRNA and dCas9-VPR used for CRISPR/dCas9-mediated activation of gene expression are listed in Supplementary Table 5. Nuclease-null Cas9 (dCas9) fused with VP64-65-Rta (VPR) was cloned from SP-dCas9-VPR (a gift from G. Church; Addgene plasmid #63798) and then subcloned into pCL6 vector with a blasticidin-resistant marker. gRNA sequences (Supplementary Table 6) targeting the transcriptional start site
of each specific gene were obtained from public databases (http://samgenome-engineering.org/ and http://www.genscript.com/gRNA-database.html)13. gBlocks Gene Fragments were used to generate single-guide RNAs (sgRNAs) and were purchased from Integrated DNA Technologies, Inc. Each gRNA was subcloned into pCLe vector with a dsRed reporter. Patient-derived pre-B ALL cells transduced with either GFP-tagged inducible PAX5 or an empty vector were transduced with pCLe-h-cMV-D-CA9-VPR-Blast. Blastin-resistant cells were used for subsequent transduction with pCLe-h-cMV-gRNA-dsRed, and dsRed-ε cells were further analysed by flow cytometry. For each target gene, 2–3 sgRNA clones were pooled together to generate lentiviruses. Non-targeting gRNA was used as control. To elucidate the mechanistic contribution of PAX5 targets, the percentage of GFP+ cells carrying gRNAs for each target gene was monitored by flow cytometry upon inducible activation of GFP-tagged PAX5 or an empty vector in patient-derived pre-B ALL cells in competitive-growth assays. Western blotting. Cells were lysed in Celllytic buffer (Sigma–Aldrich) supplemented with a 1% protease inhibitor cocktail (Thermo Fisher Scientific). A total of 20 μg of protein mixture per sample was separated on NuPAGE (Invitrogen) 4–12% Bis-Tris gradient gels or 4–20% Mini-PROTEAN TGX precast gels, and transferred onto nitrocellulose membranes (Bio-Rad). The primary antibodies used are listed in Supplementary Table 7. For protein detection, the WesternBreeze Immunodetection System (Invitrogen) was used, and light emission was detected by either film exposure or the BioSpectrum Imaging system (UPV). Flow cytometry. Approximately 106 cells per sample were resuspended in PBS blocked using Fc blocker for 10 min on ice, followed by staining with the appropriate dilution of the antibodies or their respective isotype controls for 15 min on ice. Cells were washed and resuspended in PBS with propidium iodide (0.2 μg/ml) or DAPI (0.75 μg/ml) as a dead-cell marker. The antibodies used for flow cytometry are listed in Supplementary Table 7. For competitive-growth assays, the percentage of GFP+ cells was monitored by flow cytometry. For annexin V staining, annexin V binding buffer (BD Bioscience) was used instead of PBS and 7-aminoactinomycin D (7AAD; BD Bioscience) instead of propidium iodide. Phycerothyrin-labelled annexin V was purchased from BD Bioscience. For BrdU staining, the BrdU Flow Kit was purchased from BD Bioscience and used according to the manufacturer's protocol. Colony-forming assay. Methylocelulose colony-forming assays were performed with 10,000 BCR–ABL1 pre-B ALL cells. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers were counted after 14 days. Cell viability assay and determination of viable cell counts. Cell viability upon the genetic loss of function of target genes and/or inducible expression of PAX5 was monitored by flow cytometry using propidium iodide (0.2 μg/ml) as a dead-cell marker. To study the effects of an AMPK inhibitor (BML275), glucocorticoids (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone) treated cells were irradiated with 1 J/cm² of 3-OMG and d-allose, 40,000 human or mouse leukaemia cells were seeded in MethoCult medium (StemCell Technologies), and colonies were counted after 14 days. Colony-forming assay. Colony-forming assays were performed with 10,000 BCR–ABL1 pre-B ALL cells. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers were counted after 14 days. Colony-forming assay. Colony-forming assays were performed with 10,000 BCR–ABL1 pre-B ALL cells. Cells were resuspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers were counted after 14 days. Cell viability assay and determination of viable cell counts. Cell viability upon the genetic loss of function of target genes and/or inducible expression of PAX5 was monitored by flow cytometry using propidium iodide (0.2 μg/ml) as a dead-cell marker. To study the effects of an AMPK inhibitor (BML275), glucocorticoids (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone), CNR2 agonist (HU308), or TXNIP agonists (dexamethasone and prednisolone) treated cells were irradiated with 1 J/cm² of 3-OMG and d-allose, 40,000 human or mouse leukaemia cells were seeded in MethoCult medium (StemCell Technologies), and colonies were counted after 14 days.

Glucose and ATP measurements. Extracellular glucose levels were measured using the Amplexer Red Glucose/Glucose Oxidase Assay Kit (Invitrogen), according to the manufacturer's protocol. Glucose concentrations were measured in fresh and spent medium. Total ATP levels were measured using the ATP Bioluminescence Assay Kit CL5 II (Roche) according to the manufacturer's protocol. In fresh medium, 1 × 106 cells per well were transfected and treated as indicated in the figure legends. Relative levels of glucose consumed and total ATP are shown. All values were normalized to cell numbers (Figs 1b, c, 2c, glucose uptake), 3a and Extended Data Figs 2c, 4f, 6d) or total protein (Fig. 2c, ATP levels). Numbers of viable cells were determined by applying trypan blue dye exclusion, using the Vi-CELL Cell Counter (Beckman Coulter). Metabolic assays using the XFe24 Flux Analyzer. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using a Seahorse XF24 Flux Analyzer with an XF Cell Mito Stress Test Kit and XF Glycolysis Stress Test Kit (Seahorse Bioscience) according to the manufacturer's instructions. All compounds and materials were obtained from Seahorse Bioscience. In brief, 1.5 × 106 cells per well were plated using Cell-Tak (BD Biosciences). Following incubation in XF-Base medium supplemented with glucose and Glutamax for 1 h at 37 °C (non-CO2 incubator) for pH stabilization, OCR was measured at the resting stage (basal respiration in XF Base medium supplemented with Glutamax and glucose) and in response to oligomycin (1 μmol/l; mitochondrial ATP production), mitochondrial uncoupler FCCP (5 μmol/l; maximal respiration), and respiratory chain inhibitor antimycin and rotenone (1 μmol/l). Spare respiratory capacity is the difference between maximal respiration and basal respiration. ECAR was measured under specific conditions to generate glycolytic profiles. Following incubation in glucose-free XF Base medium supplemented with Glutamax for 1 h at 37 °C (non-CO2 incubator) for pH stabilization, basal ECAR was measured. Following measurement of the glucose-deprived, basal ECAR, changes in ECAR upon the sequential addition of glucose (10 mmol/l; glycolysis), oligomycin (1 μmol/l; glycolytic capacity), and 2-deoxyglucose (0.1 mmol/l) were measured. Glycolytic reserve was determined as the difference between oligomycin-stimulated glycolytic capacity and glucose-stimulated glycolysis. All values were normalized to cell numbers (Extended Data Fig. 2c) or total protein (Extended Data Figs 3a, 7a, b, 8f) and are shown as the fold change relative to basal ECAR or OCR.

Metabolite extraction and mass-spectrometry-based analysis. Metabolite extraction and mass-spectrometry-based analysis were performed as described previously44. Metabolites were extracted from 2 × 106 cells per sample using the methanol/water/chloroform method. After incubation at 37 °C for the indicated time, cells were rinsed with 150 mM ammonium acetate (pH 7.3), and 400 μl 100% methanol (Optima* LC/MS, Fisher) and then 400 μl cold water (HPLC-Grade, Fisher) was added to cells. A total of 10 nmol norvaline (Sigma) was added as internal control, followed by 400 μl cold chloroform (HPLC-Grade, Fisher). Samples were vortexed three times over 15 min and spun down at top speed for 5 min at 4 °C. The top layer (aqueous phase) was transferred to a new Eppendorf tube, and samples were dried on Vacufuge Plus (Eppendorf) at 30 °C. Extracted metabolites were stored at −80 °C. For mass-spectrometry-based analysis, the metabolites were resuspended in 70% acetonitrile and 5 μl used for analysis with a mass spectrometer. The mass spectrometer (Q Exactive, Thermo Scientific) was coupled to an Ulitmate3000 RSLCnano HPLC. The chromatography was performed with 5 mM NH4AcO (pH 9.9) and acetoniitrite at a flow rate of 300 μl/min at 85% acetonitrile going to 5% acetonitrile at 18 min, followed by an isocratic step to 27 min and re-equilibration to 34 min. The separation was achieved on a Luna 5u NH2 (150 × 2 mm) Phenomenex. The Q Exactive was run in polarity switching mode (+3 kV−/−2.25 kV). Metabolites were detected based on their m/z ratio (500–2000 Da) and retention time. The identification of metabolites was performed as area-under-the-curve (AUC) with TraceFinder 3.1 (Thermo Scientific). Data analysis was performed in R (https://www.r-project.org/), and data were normalized to the number of cells. Relative amounts were log-transformed, median-centred and are shown as a heat map.

Oncogenic priming of Mbl1–Crc. Bcr-TSL–BCR/ABL B-cell precursor cells. To generate a model for pre-leukaemic B cell precursors expressing BCR–ABL1, BCR–ABL1 knock-in mice were crossed with Mbl1–Cre deleter strain (Mbl1–Cre; Bcr-TSL–BCR/ABL) for excision of a stop-cassette in early pre-B cells. Bone marrow cells collected from Mbl1–Cre; Bcr-TSL–BCR/ABL1 mice cultured in the presence of 2 μg/ml tamoxifen with vehicle control or a combination of OAA (8 mmol/l), DMS (8 mmol/l) and insulin (210 mmol/l). Following a week of priming, cells were maintained and expanded in the presence of IL-7, supplemented with vehicle control or a combination of OAA (0.8 mmol/l) and DMS (0.8 mmol/l) for 4 weeks. Pre-B cells from Mbl1–Cre; Bcr-TSL–BCR/ABL1 mouse expressed low levels of BCR–ABL1 tagged peaks were called by the MACS peak-caller by comparing read density in the ChIP experiment relative to the input chromatin control reads, and are shown as bars under each wiggle track. Gene models are shown in UCSG genome browser hg19.
to GFP, and were analysed by flow cytometry for surface expression of GFP and CD19. The methylcellulose colony-forming assays were performed with 10,000 cells treated with vehicle control or metabolites. Cells were suspended in mouse MethoCult medium (StemCell Technologies) and cultured on 3-cm diameter dishes, with an extra water supply dish to prevent evaporation. Images were taken and colony numbers counted after 14 days.

For in vivo transplantation experiments, cells were treated with vehicle control or metabolites (OAA/DM) for 6 weeks. One million cells were intravenously injected into sublethally irradiated (250 cGy) 6–8-week-old female NSG mice (n = 7 per group). Mice were randomly allocated into each group, and the minimal number of mice in each group was calculated by using the ‘cpower’ function in R/Hmisc package. No blinding was used. Each mouse was killed when it became terminally sick and showed signs of leukaemia burden (hunched back, weight loss and inability to move). The bone marrow and spleen were collected for flow cytometry analyses for leukaemia infiltration (CD19, B220). After 63 days, all remaining mice were killed and bone marrow and spleens from all mice were analysed by flow cytometry. Statistical analysis was performed using the Mantel–Cox log-rank test. All mouse experiments were in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee.

**In vivo experiments.** Following cytokine-independent proliferation, BCR-ABL1-transformed Lkb1fl/fl or AMPKa2fl/fl pre-B ALL cells were transduced with 4-OHT-inducible Cre or an empty vector control. For ex vivo deletion, deletion was induced 24 h before injection. For in vivo deletion, deletion was induced by 4-OHT (0.4 mg per mouse; intraperitoneal injection). Approximately 10⁶ cells were injected into each sublethally irradiated (250 cGy) NOD/SCID mouse. Seven mice per group were injected via the tail vein.

We randomly allocated 6–8-week-old female NOD/SCID or NSG mice into each group. The minimal number of mice in each group was calculated using the ‘cpower’ function in R/Hmisc package. No blinding was used. When a mouse became terminally sick and showed signs of leukaemia burden (hunched back, weight loss and inability to move), it was killed and the bone marrow and/or spleen were collected for flow cytometry analyses for leukaemia infiltration. Statistical analysis was performed by Mantel–Cox log-rank test. In vivo expansion and leukaemia burden were monitored by luciferase imaging. Bioimaging of leukaemia progression in mice was performed at the indicated time points using an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen). n-Luciferin (Promega) dissolved in PBS was injected intraperitoneally at a dose of 2.5 mg per mouse 15 min before measuring the luminescence signal. General anesthesia was induced with 5% isoflurane and continued during the procedure with 2% isoflurane introduced through a nose cone. All mice were killed when it became terminally sick and showed signs of leukaemia burden (hunched back, weight loss and inability to move). The bone marrow and spleen were collected for flow cytometry analyses for leukaemia infiltration (CD19, B220). After 63 days, all remaining mice were killed and bone marrow and spleens from all mice were analysed by flow cytometry. Statistical analysis was performed using the Mantel–Cox log-rank test. All mouse experiments were in compliance with institutional approval by the University of California, San Francisco Institutional Animal Care and Use Committee.

**Statistical analysis and reproducibility.** Data are shown as mean ± s.d. unless stated. Statistical significance was analysed by using Graphpad Prism software or R software (https://www.r-project.org/) by using two-tailed t-test, two-way ANOVA, or log-rank test as indicated in figure legends. Significance was considered at P < 0.05. For in vitro experiments, no statistical methods were used to predetermine the sample size. For in vivo transplantation experiments, the minimal number of mice in each group was calculated through use of the ‘cpower’ function in the R/Hmisc package. No animals were excluded. Overall survival and relapse-free survival data were obtained from GEO accession number GSE11877 (refs 35, 36) and TCGA. Kaplan–Meier survival analysis was used to estimate overall survival and relapse-free survival. Patients with high risk pre-B ALL (COG clinical trial, P9906, n = 207; Supplementary Table 10) were segregated into two groups on the basis of high or low mRNA levels with respect to the median mRNA values of the probe sets for the gene of interest. A log-rank test was used to compare survival differences between patient groups. R package ‘survival’ Version 2.35-8 was used for the survival analysis and Cox proportional hazards regression model in R package for the multivariate analysis (https://www.r-project.org/). The investigators were not blinded to allocation during experiments and outcome assessment. Experiments were repeated to ensure reproducibility of the observations.

**Data availability.** Gel scans are provided in Supplementary Fig. 1. Gene expression data were obtained from the GEO database accession numbers GSE32330 (ref. 12), GSE52870 (ref. 37), and GSE38463 (ref. 38). Patient-outcome data were derived from the National Cancer Institute TARGET Data Matrix of the Children's Oncology Group (COG) Clinical Trial P9906 (GSE11877)35,36 and from TCGA (the Cancer Genome Atlas). GEO accession details are provided in Supplementary Tables 9 and 10. ChIP–seq tracks for PAX5, IKZF1, EBF1 and TCF3 antibodies in a normal B-cell sample (ENCODE GM12878, UCSC genome browser) on INSR, GLUT1, GLUT3, GLUT6, HK2, G6PD, NR3C1, TXNIP, C1R2 and LKB1 gene promoter regions are shown in UCSC genome browser hg19. All other data are available from the corresponding author upon reasonable request.
Extended Data Figure 1 | Frequent genetic lesions of B-lymphoid transcription factors in B-cell lineage leukaemia. a, Gene expression of B-lymphoid transcription factors (top) as well as positive (middle) and negative (bottom) regulators of glucose uptake and energy supply upon inducible restoration of Pax5 (GEO accession number: GSE52870) in haploinsufficient pre-B leukaemia cells. b, Lesions in Pax5, Ikzf1, Ebf1, Tcf3 and Tcf3 were studied in clinical trials for B-lymphoid ALL in children (P9906; n = 187; top) and adults (MDACC; n = 92; bottom). Red and grey boxes denote patient samples with detected lesions. c, Protein expression of PAX5 and IKZF1 was examined by western blot in ten patient-derived pre-B ALL samples. The control samples were CD19+ B cells from four healthy donors. d, ChIP–seq analysis for binding of B-lymphoid transcription factors in human B cells (ENCODE cell ID: GM12878) to promoter regions of molecules implicated in positive (INSR, GLUT1, GLUT3, GLUT6, HK2, G6PD, LKB1) and negative (NR3C1, TXNIP, CNR2) regulation of glucose uptake and utilization. e, Recruitment of PAX5 was confirmed by quantitative ChIP in patient-derived pre-B ALL cells. Data shown as mean ± s.d. from three independent experiments and assessed by two-tailed t-test. For gel source data, see Supplementary Fig. 1.
Extended Data Figure 2 | The B-lymphoid transcription factor PAX5 functions as a metabolic gatekeeper. 

a, Protein levels of PAX5 and IKZF1 in haploinsufficient patient-derived pre-B ALL cells and pre-B ALL cells expressing functional PAX5 and IKZF1. 
b, Number of viable cells and cell viability upon inducible activation of PAX5 in haploinsufficient patient-derived pre-B ALL (PAX5Δ1−) cells. 
c, To test whether Pax5 functions as metabolic gatekeeper, BCR–ABL1-induced changes in glycolytic activity and capacity (ECAR), glucose uptake, and ATP levels (normalized to cell numbers) were studied in Pax5 wild-type and Pax5 haploinsufficient pre-B cells in the presence or absence of a BCR–ABL1-transgene. Data shown as mean ± s.d. from three independent experiments and assessed by two-tailed t-test (b, left; c) or two-way ANOVA (b, right). For gel source data, see Supplementary Fig. 1.
Extended Data Figure 3 | Divergent metabolic characteristics of myeloid and B-lineage leukaemia. a, Glycolytic reserve (ECAR) and mitochondrial functions (OCR) in patient-derived myeloid (CML) and B-lymphoid (Ph⁺ ALL) leukaemia samples (n = 5, each in triplicate). Values were normalized to total protein and are shown as mean ± s.d., assessed by two-tailed t-test. b, Mouse pre-B ALL cells were reprogrammed into myeloid differentiation using a doxycycline-inducible TetOn-Cebpa vector system, and characterized by flow cytometry (representative results from three independent experiments). c, Heat map of gene expression of glucose uptake and metabolism regulators (GEO accession number: GSE32330). d, Western blots of mouse pre-B ALL cells upon B-to-myeloid cell reprogramming to verify gene expression changes. For gel source data, see Supplementary Fig. 1.
Extended Data Figure 4 | See next page for caption.
Extended Data Figure 4 | The energy stress sensor LKB1–AMPK plays a pro-survival role and modulates glucose uptake and energy supply in pre-B ALL. a, Lkb1<sup>fl/fl</sup> mice were crossed with Cre-deleter strains for deletion at early pre-B-cell stages (Mb1) and in fully mature B cells (Cd21). B-cell populations in bone marrow and spleen (n = 3 litter mates) were characterized by flow cytometry analysis. b, The catalytic subunit of Ampk has two isoforms, α<sub>1</sub> and α<sub>2</sub>. Analysis of published gene expression data (GSE38463)<sup>38</sup> revealed that expression of the α<sub>1</sub>-form peaks at later stages of B-cell development, whereas expression of both Lkb1 and the α<sub>2</sub>-form of Ampk peaks in pre-B cells. For this reason, we studied the consequences of inducible ablation of Lkb1 and Ampka2 in mouse models of BCR–ABL1-transformed pre-B ALL cells. Protein levels of Lkb1 and Ampkα2 were verified by western blots. c, Viable cell counts upon Cre-mediated deletion of Lkb1 or Ampka2 or on treatment with an empty vector (EV). d, Apoptosis following Lkb1 deletion was monitored by annexin V/7-aminoactinomycin D (7AAD) staining. e, Colony-forming ability was assessed by serial re-plating upon deletion of Lkb1 in pre-B ALL cells. f, Glucose uptake and ATP levels (normalized to cell numbers) were measured following Cre-mediated deletion of Ampka2. g, Luciferase bioimaging of transplant recipient mice injected with Lkb1<sup>fl/fl</sup> pre-B ALL cells transduced with 4-OHT-inducible Cre or an empty vector and treated with tamoxifen (0.4 mg per mouse; n = 7 per group). h, Overall survival was assessed by a Kaplan–Meier analysis (P value calculated by Mantel–Cox log-rank test). i, Leukaemia samples developed in recipient mice (Fig. 2d) were genotyped for the presence of either floxed or deleted Lkb1 and Ampka2 alleles (n = 3 mice). Representative FACS plots and images from three independent experiments are shown (a, d, e). Data shown as mean ± s.d. from three independent experiments and assessed by two-way ANOVA (c) or two-tailed t-test (e, f). For gel source data, see Supplementary Fig. 1.
Patients with high risk pre-B ALL (COG clinical trial, P9906)

a. Children with high-risk pre-B ALL (P9906, n = 207) were divided into two groups based on higher- or lower-than-median mRNA levels of LKB1 (a) or AMPKα2 (b). Overall survival of patients was assessed in the two groups by Kaplan–Meier analysis. A log-rank test was used to assess statistical significance (a–d).

e. Frequencies of somatic mutations in the coding regions of EBF1 (top, blue), IKZF1 (middle, grey) and PAX5 (bottom, red) from the Catalogue of Somatic Mutations in Cancer (COSMIC) database are plotted for pre-B ALL and various subtypes of mature B-cell lymphoma. Somatic mutations in the 5′ UTR regions of EBF1, IKZF1 and PAX5 frequently represent by-products of somatic hypermutation during normal B-cell development and are not included in this analysis. PCNL, primary central nervous system lymphoma.

Patients with AML (TCGA)

c. Adults with acute myeloid leukaemia (AML; The Cancer Genome Atlas, n = 184) were divided into two groups based on higher- or lower-than-median mRNA levels of LKB1 (c) or AMPKα2 (d). Overall survival of patients was assessed in the two groups by Kaplan–Meier analysis. A log-rank test was used to assess statistical significance (a–d).

e. Frequencies of somatic mutations in the coding regions of EBF1 (top, blue), IKZF1 (middle, grey) and PAX5 (bottom, red) from the Catalogue of Somatic Mutations in Cancer (COSMIC) database are plotted for pre-B ALL and various subtypes of mature B-cell lymphoma. Somatic mutations in the 5′ UTR regions of EBF1, IKZF1 and PAX5 frequently represent by-products of somatic hypermutation during normal B-cell development and are not included in this analysis. PCNL, primary central nervous system lymphoma.
Extended Data Figure 6 | Divergent functions of Lkb1 in BCR-ABL1-driven pre-B ALL and myeloid leukaemia. a, Staining of Lkb1fl/fl BCR-ABL1 myeloid (CML-like) and B-lineage (Ph+ ALL-like) leukaemia cells with (Cre) or without (empty vector (EV)) deletion of Lkb1 for the surface markers CD19, B220 (B-lymphoid), Sca-1 and CD13 (myeloid). b, Phosphorylation of AMPKα-T172, AKT-S473 and S6-S235 and protein levels of cell-cycle checkpoint molecules Arf, p53 and p27 following Lkb1-deletion. c, Viable cell counts upon deletion of Lkb1. d, Glucose uptake and ATP levels (normalized to cell numbers) in myeloid and B-lymphoid leukaemia cells upon Lkb1-deletion (n = 6). Data are shown as mean ± s.d. e, Cell-cycle analyses were performed by measuring BrdU incorporation in combination with 7AAD staining. Percentages of cells in G0/G1, S, and G2/M phases are shown. Viability following Lkb1 deletion was monitored by annexin V/7AAD staining. Representative FACS plots from three independent experiments are shown (a, e). Data shown as mean ± s.d. from three independent experiments (c, e), assessed by two-tailed t-test (c, e). For gel source data, see Supplementary Fig. 1.
Extended Data Figure 7  |  Activity of the energy-stress sensor LKB1 represents a specific vulnerability of B-lymphoid leukaemia.

a, b, Glycolytic profiles (ECAR; a) and mitochondrial functions (OCR; b) upon Lkb1-deletion in B-lymphoid leukaemia cells with (left) or without (right) B-to-myeloid cell reprogramming. Values were normalized to total protein (n = 6). c, AMP levels in sorted B-lymphoid and B-to-myeloid reprogrammed cells are shown as log2-transformed relative amounts (the amount in Lkb1-deleted cells divided by the average amount in control samples), and data were baseline-centred (the baseline is equal to the average amount in control samples; n = 3). d, Phosphorylation of Ampkα-T172, Ulk1-S555, Raptor-S792 and Acc-S79 was assessed by western blots. Data shown as mean ± s.d. and assessed by two-tailed t-test (a–c).

For gel source data, see Supplementary Fig. 1.
Extended Data Figure 8 | See next page for caption.
Extended Data Figure 8 | Small molecule inhibition of AMPK in human pre-B ALL. a, Human leukaemia and lymphoma cells (n = 4 biological replicates for B-cell lymphoma and pre-B ALL; n = 3 biological replicates for CML; each in triplicate) were treated with BML275 (72 h), and relative viability was assessed. b, Apoptosis was examined by annexin V/7AAD staining in patient-derived pre-B ALL samples (n = 3) upon treatment with BML275 (10 μmol/l). c, Phospho-ACC-S79 in patient-derived pre-B ALL samples (n = 5) following overnight treatment with control (−) or BML275 (+, 10 μmol/l) was assessed. d, Phosphorylation of S6-S235/236 and Akt-S473 in patient-derived pre-B ALL samples (n = 6) following overnight treatment with control (−) or BML275 (+, 10 μmol/l) was assessed. e, Levels of AMP (normalized to cell numbers) in patient-derived CML (CML5 and CML6) and Ph+ ALL (ICN1 and PDX2) cells following treatment with control or BML275 (10 μmol/l for 12 h). Plotted are log2-transformed average relative amounts (amount in cells treated with BML275 divided by the average amount of that in control cells; two cases per group; each in triplicate); data were median-centred. Median-centring was performed separately for CML5, CML6, ICN1 and PDX2 samples. f, Patient-derived CML (left) and pre-B ALL (middle) cells as well as MYC-driven B-cell lymphoma cell lines (right) were treated with BML275 (10 μmol/l) or vehicle control for 6 h. Glycolytic profiles (ECAR) and mitochondrial functions (OCR) were measured (normalized to total protein; n = 6; f). Data shown as mean ± s.d. and assessed by two-tailed t-test (e, f).
Extended Data Figure 9 | See next page for caption.
Extended Data Figure 9 | Mechanistic contribution of PAX5 targets.

a, b, Representative FACS plots from CRISPR-based gene editing experiments (a). CRISPR complexes were delivered to patient-derived PAX5-haploinsufficient pre-B ALL cells along with RFP-tagged gRNAs to direct dCas9 (CRISPR-mediated gene activation) or Cas9 (CRISPR-mediated gene deletion) to specific PAX5 target genes (for example, NR3C1; left). Upon inducible activation of GFP-tagged PAX5 or an empty vector (EV) in patient-derived pre-B ALL cells, enrichment or depletion of GFP+ cells carrying RFP-tagged gRNAs (RFP+) was monitored by flow cytometry (right; NT, non-targeting; g-53, gRNA clone 53 for deletion of NR3C1). Changes in percentage of GFP+ cells carrying the indicated gRNAs following induction, as compared to cells carrying the non-targeting gRNA (b).

c, d, In mouse pre-B ALL models for genetic loss of Nr3c1, Cnr2, and Txinp function, responses to prednisolone (Pred) were measured (c) and protein levels of Nr3c1, Txnip and Cnr2 were examined (d). e, In a patient-derived PAX5-haploinsufficient pre-B ALL sample (PAX5Δ; left), dexamethasone responses upon inducible activation of PAX5 or empty vector were measured. In a patient-derived PAX5 wild-type pre-B ALL sample (PAX5WT; right), effects of DN-PAX5 on dexamethasone responses were measured. Likewise, dose–response curves for dexamethasone were measured in two patient-derived pre-B ALL samples carrying either wild-type or deleted IKZF1 upon induction of DN-IKZF1 or IKZF1 expression, respectively. Data shown as mean ± s.d. from three independent experiments and assessed by two-tailed t-test (b) or two-way ANOVA (c, e).
Extended Data Figure 10 | Targeting AMPK, CNR2 and TXNIP in combination with glucocorticoids. 

a, Three different patient-derived pre-B ALL samples were treated with the AMPK inhibitor BML275, prednisolone or a combination of the two for 72 h. 

b, Three different patient-derived pre-B ALL samples were treated with the CNR2 agonist HU308, prednisolone (Pred), or a combination of the two for 72 h. 

c, d, Three different patient-derived pre-B ALL samples were treated with the TXNIP agonist 3-O-MG (c) or d-allose (d), prednisolone, or a combination of the two for 72 h. Relative viability was assessed (a–d). Combination index (CI) values at ED50 are shown. Prednisolone concentrations used were twofold higher than those of BML275. All data shown as mean ± s.d. (n = 3 independent experiments).
Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors

Lai N. Chan, Zhengshan Chen, Daniel Braas, Jae-Woong Lee, Gang Xiao, Huimin Geng, Kadriye Nehir Cosgun, Christian Hurtz, Seyedmehdi Shojaee, Valeria Cazzaniga, Hilde Schjerven, Thomas Ernst, Andreas Hochhaus, Steven M. Kornblau, Marina Konopleva, Miles A. Pufall, Giovanni Cazzaniga, Grace J. Liu, Thomas A. Milne, H. Phillip Koeffler, Theodora S. Ross, Isidro Sánchez–García, Arndt Borkhardt, Keith R. Yamamoto, Ross A. Dickins, Thomas G. Graeber & Markus Müschen

Correction to: Nature https://doi.org/10.1038/nature21076, published online 13 February 2017.

In Fig. 3c of this Letter, the effects of CRISPR–Cas9-mediated deletion of NR3C1, TXNIP and CNR2 in patient-derived B-lineage leukaemia cells were shown. For curves depicting NR3C1 (left graph), data for TXNIP (middle graph) were inadvertently plotted. This figure has been corrected online, and the original Fig. 3c is shown as Supplementary Information to this Amendment for transparency. The error does not affect the conclusions of the Letter. In addition, Source Data files have been added for the Figs. 1–4 and Extended Data Figs. 1–10 of the original Letter.

Supplementary information is available at https://doi.org/10.1038/s41586-018-0164-5.